ANACOR TO DETAIL CHEMISTRY BEHIND LEAD COMPOUNDS

-- Company Researchers to Present Data on Discovery of AN2690, AN0128 at American Chemical Society Meeting --

Palo Alto, CA and San Francisco - Sept. 12, 2006 - Anacor Pharmaceuticals, a privately held pharmaceutical company, today announced it will make two presentations at the American Chemical Society National Meeting & Exposition this week in San Francisco. Researchers will make an oral presentation on the chemistry and discovery of AN2690, Anacor's topical antifungal drug candidate being developed for onychomycosis, a fungal infection of the toenail and nail bed, as well as a poster presentation on the discovery of AN0128, Anacor's treatment for atopic dermatitis.

The conference is being held at the Moscone Center. 

AN0128 Poster Presentation:
MEDI 332
Discovery and SAR of diphenylborinic acid picolinate esters as a potent antibacterial and anti-inflammatory agent for the treatment of skin diseases
General Poster Session
7 to 9 p.m., Wednesday, Sept. 13, Moscone Center -- Hall D

AN2690 Oral Presentation:
MEDI 296
Discovery and SAR of a boron-containing clinical molecule (AN-2690) for topical onychomycosis treatment
General Oral Session
1:30 to 4:50 p.m., Tuesday, Sept. 12, Moscone Center -- Room 103

About Anacor Pharmaceuticals
Anacor, a privately held, clinical-stage pharmaceutical company, is developing novel product candidates for inflammatory and infectious diseases based on its proprietary, small-molecule, boron-based chemistry. Initially, Anacor is focusing development efforts on dermatological disorders with AN2690 in Phase 2 trials for onychomycosis, a fungal infection of nails and nailbeds. A second product candidate, AN0128, is in Phase 2 clinical trials for atopic dermatitis.